We are live on ! Find out more

Novartis

NVS

Market cap $269B

141.46 USD

+0.48

0.34%

At close Updated Sep 22, 11:43 AM EDT

1 day

0.34%

5 days

0.63%

1 month

-10.48%

3 months

-5.02%

6 months

-4.48%

Year to date

2.11%

1 year

14.67%

5 years

70.85%

10 years

92.46%

About: Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Employees: 75,267

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 39.1%

Neutral 16.3%

Negative 44.6%

Zacks Investment Research

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Novartis halts ALS drug development after mid-stage trial failure

Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals ‌in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this year.

Novartis halts ALS drug development after mid-stage trial failure

Investors Business Daily

Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.

Zacks Investment Research

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

The Motley Fool

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a).

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness

Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.

Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness

Novartis: More Pain on the Way?

The bad diagnoses just keep on coming for the Swiss drugmaker.

Novartis: More Pain on the Way?

Focus: Novartis investors turn spotlight on M&A after trial setbacks

Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its pipeline.

Focus: Novartis investors turn spotlight on M&A after trial setbacks

Major Novartis shareholder calls for board shake-up after drug trial setbacks

A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial setbacks.

Major Novartis shareholder calls for board shake-up after drug trial setbacks

See News Rankings

Price charts implemented using Lightweight Charts™